文献速递重症综合管理与镇静镇痛

一项干预性准实验研究:快速筛查策略对改善重症患者医院内产ESBL肠杆菌目和产碳青霉烯酶微生物控制的影响

An interventional quasi-experimental study to evaluate the impact of a rapid screening strategy in improving control of nosocomial extended-spectrum beta-lactamase-producing Enterobacterales and carbapenemase-producing organisms in critically ill patients.
PubMed 文献 · Crit Care · 2022-06-07
一句话结论在低流行区ICU,直接直肠拭子LAMP快速筛查未改善感染控制,反而因阳性预测值低无法用于实施接触预防。

该12个月干预性队列研究在ICU常规筛查中比较LAMP法直接检测直肠拭子与培养法(对照期6个月),对CPO或非大肠埃希菌产ESBL肠杆菌目(nEcESBL-PE)携带者实施接触预防。共纳入1043例患者。干预期与对照期分别有92/147(62.6%)和47/86(54.7%)入院筛查的高危患者符合早期停用预防性接触预防的条件。LAMP对CPO的阳性预测值为44.0%、阴性预测值为99.9%,对nEcESBL-PE的阳性预测值为55.6%、阴性预测值为98.2%。因结果通知与解读困难,干预期从入院到停用预防性接触预防的中位时间从80.5小时(95%CI 71.5-132.1)延长至88.3小时(95%CI 57.7-103.7)(p=0.47)。因阳性预测值差,不得不停止使用LAMP实施接触预防。nEcESBL-PE和CPO获得率无差异。结论:在低流行区,直接直肠拭子LAMP快速筛查策略对感染控制无益。

要点

  • 在低流行区ICU,直接直肠拭子LAMP快速筛查对nEcESBL-PE/CPO感染控制无益。
  • LAMP对CPO的阳性预测值44.0%、阴性预测值99.9%;对nEcESBL-PE的阳性预测值55.6%、阴性预测值98.2%。
  • 因阳性预测值差,研究不得不停止使用LAMP实施接触预防。
  • 干预期从入院到停用预防性接触预防的中位时间88.3小时(95%CI 57.7-103.7)vs 对照期80.5小时(95%CI 71.5-132.1),p=0.47。
  • nEcESBL-PE和CPO获得率无差异。

适用人群与场景

  • ICU患者,常规ICU筛查,干预性12个月队列研究,共纳入1043例患者。
  • 对CPO或非大肠埃希菌产ESBL肠杆菌目(nEcESBL-PE)携带者实施接触预防。

诊断标准与关键阈值

  • 接触预防(CP)实施标准:CPO或非大肠埃希菌产ESBL肠杆菌目(nEcESBL-PE)携带者。

处置流程与药物剂量

  • 干预期使用环介导等温扩增(LAMP)法直接检测直肠拭子,对照期使用培养法,均为常规ICU筛查。
  • 对CPO或nEcESBL-PE携带者实施接触预防。
  • 因LAMP阳性预测值差,研究停止使用LAMP实施接触预防。

研究设计与关键结果

  • 研究类型:干预性12个月队列研究(准实验),比较LAMP法与培养法,对照期6个月。
  • 样本量:共纳入1043例患者。
  • 干预期与对照期分别有92/147(62.6%)和47/86(54.7%)入院筛查的高危患者符合早期停用预防性接触预防的条件。
  • LAMP对CPO的阳性预测值44.0%、阴性预测值99.9%;对nEcESBL-PE的阳性预测值55.6%、阴性预测值98.2%。
  • 因结果通知与解读困难,干预期从入院到停用预防性接触预防的中位时间从80.5小时(95%CI 71.5-132.1)延长至88.3小时(95%CI 57.7-103.7)(p=0.47)。
  • 因阳性预测值差,不得不停止使用LAMP实施接触预防。
  • nEcESBL-PE和CPO获得率无差异。

证据类型、等级与局限

  • 证据类型:干预性准实验研究(12个月队列研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在低流行区ICU,直接直肠拭子LAMP快速筛查策略对感染控制无益,不应替代培养法用于实施接触预防。
  • LAMP阳性预测值低(CPO 44.0%,nEcESBL-PE 55.6%),不宜依据LAMP阳性结果启动接触预防;阴性预测值高(CPO 99.9%,nEcESBL-PE 98.2%),但原文未据此给出推荐。
  • 快速筛查还需考虑结果通知与解读环节,否则可能延长停用预防性接触预防的时间(干预期88.3小时 vs 对照期80.5小时,p=0.47)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Rapid molecular tests could accelerate the control of extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE) and carbapenemase-producing organisms (CPO) in intensive care units (ICUs).

OBJECTIVE AND METHODS: This interventional 12-month cohort study compared a loop-mediated isothermal amplification (LAMP) assay performed directly on rectal swabs with culturing methods (control period, 6 months), during routine ICU screening. Contact precautions (CP) were implemented for CPO or non-E. coli ESBL-producing Enterobacterales (nEcESBL-PE) carriers. Using survival analysis, we compared the time intervals from admission to discontinuation of unnecessary preemptive CP among patients at-risk and the time intervals from screening to implementation of CP among newly identified carriers. We also compared diagnostic performances, and nEcESBL-PE/CPO acquisition rates. This study is registered, ISRCTN 23588440.

RESULTS: We included 1043 patients. During the intervention and control phases, 92/147 (62.6%) and 47/86 (54.7%) of patients at-risk screened at admission were candidates for early discontinuation of preemptive CP. The LAMP assay had a positive predictive value (PPV) of 44.0% and a negative predictive value (NPV) of 99.9% for CPO, and 55.6% PPV and 98.2% NPV for nEcESBL-PE. Due to result notification and interpretation challenges, the median time from admission to discontinuation of preemptive CP increased during the interventional period from 80.5 (95% CI 71.5-132.1) to 88.3 (95% CI 57.7-103.7) hours (p = 0.47). Due to the poor PPV, we had to stop using the LAMP assay to implement CP. No difference was observed regarding the incidence of nEcESBL-PE and CPO acquisition.

CONCLUSION: A rapid screening strategy with LAMP assays performed directly on rectal swabs had no benefit for infection control in a low-endemicity setting.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Martischang R, François P, Cherkaoui A, et al. An interventional quasi-experimental study to evaluate the impact of a rapid screening strategy in improving control of nosocomial extended-spectrum beta-lactamase-producing Enterobacterales and carbapenemase-producing organisms in critically ill patients. Crit Care. 2022. PMID: 35672757. doi:10.1186/s13054-022-04027-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。